+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Final trial report of sentinel-node biopsy versus nodal observation in melanoma



Final trial report of sentinel-node biopsy versus nodal observation in melanoma



New England Journal of Medicine 370(7): 599-609



Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial. We evaluated outcomes in 2001 patients with primary cutaneous melanomas randomly assigned to undergo wide excision and nodal observation, with lymphadenectomy for nodal relapse (observation group), or wide excision and sentinel-node biopsy, with immediate lymphadenectomy for nodal metastases detected on biopsy (biopsy group). Results No significant treatment-related difference in the 10-year melanoma-specific survival rate was seen in the overall study population (20.8% with and 79.2% without nodal metastases). Mean (± SE) 10-year disease-free survival rates were significantly improved in the biopsy group, as compared with the observation group, among patients with intermediate-thickness melanomas, defined as 1.20 to 3.50 mm (71.3 ± 1.8% vs. 64.7 ± 2.3%; hazard ratio for recurrence or metastasis, 0.76; P=0.01), and those with thick melanomas, defined as >3.50 mm (50.7 ± 4.0% vs. 40.5 ± 4.7%; hazard ratio, 0.70; P=0.03). Among patients with intermediate-thickness melanomas, the 10-year melanoma-specific survival rate was 62.1 ± 4.8% among those with metastasis versus 85.1 ± 1.5% for those without metastasis (hazard ratio for death from melanoma, 3.09; P<0.001); among patients with thick melanomas, the respective rates were 48.0 ± 7.0% and 64.6 ± 4.9% (hazard ratio, 1.75; P=0.03). Biopsy-based management improved the 10-year rate of distant disease-free survival (hazard ratio for distant metastasis, 0.62; P=0.02) and the 10-year rate of melanoma-specific survival (hazard ratio for death from melanoma, 0.56; P=0.006) for patients with intermediate-thickness melanomas and nodal metastases. Accelerated-failure-time latent-subgroup analysis was performed to account for the fact that nodal status was initially known only in the biopsy group, and a significant treatment benefit persisted. Biopsy-based staging of intermediate-thickness or thick primary melanomas provides important prognostic information and identifies patients with nodal metastases who may benefit from immediate complete lymphadenectomy. Biopsy-based management prolongs disease-free survival for all patients and prolongs distant disease-free survival and melanoma-specific survival for patients with nodal metastases from intermediate-thickness melanomas. (Funded by the National Cancer Institute, National Institutes of Health, and the Australia and New Zealand Melanoma Trials Group; ClinicalTrials.gov number, NCT00275496.).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053242084

Download citation: RISBibTeXText

PMID: 24521106

DOI: 10.1056/nejmoa1310460


Related references

Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report'. British Journal of Dermatology 172(3): 571-573, 2015

Sentinel-node biopsy or nodal observation in melanoma. Current Oncology Reports 9(5): 401, 2007

Sentinel node followed by completion lymph node dissection versus nodal observation: staging or therapeutic? Controversy continues despite final results of MSLT-1. Melanoma Research 24(4): 291-294, 2014

Sentinel lymph node biopsy or nodal observation in melanoma: study of an Italian series. Giornale Italiano di Dermatologia e Venereologia 148(3): 299-305, 2013

Sentinel lymph node biopsy or nodal observation in melanoma: a prospective study of patient choices. Dermatologic Surgery 37(2): 199-206, 2011

No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report. British Journal of Dermatology 172(3): 566-571, 2015

False-negative sentinel lymph node biopsy resulting from obstruction of lymphatic basin by nodal metastasis: a case report of malignant melanoma. Journal of Dermatology 38(11): 1121-1124, 2011

Compound Synthesis or Growth and Development of Roots/Stomata Regulate Plant Drought Tolerance or Water Use Efficiency/Water Uptake Efficiency. Journal of Agricultural and Food Chemistry 66(14): 3595-3604, 2018

Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast 21(5): 678-681, 2013

Sentinel node biopsy and selective dissection for melanoma nodal metastases. Tumori 84(1): 24-28, 1998

Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. Journal of Clinical Oncology 34(10): 1079-1086, 2016

Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. Cancer Medicine 5(10): 2832-2840, 2016

US scan and sentinel node biopsy in the diagnosis of nodal metastases in patients with melanoma. European Journal of Cancer 37(Suppl. 6): S82, 2001

Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma. Annals of Surgical Oncology 19(4): 1100-1106, 2012

Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases. European Journal of Cancer 34(Suppl. 3): S7-11, 1998